NEW YORK – Canbridge Pharmaceuticals said on Thursday that it received approval from the Taiwan Food and Drug Administration to market neratinib (Puma Biotechnology's Nerlynx) as an extended adjuvant treatment for adult patients with early-stage, HER2-positive breast cancer after treatment with trastuzumab (Genentech's Herceptin).